Sutro Biopharma shares are trading lower. The company announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin in combination with bevacizumab for patients with epithelial ovarian cancer in a poster presentation at the 2024 ESMO Congress.
Portfolio Pulse from Benzinga Newsdesk
Sutro Biopharma's shares are declining following the release of updated data from their Phase 1b study of luveltamab tazevibulin in combination with bevacizumab for epithelial ovarian cancer, presented at the 2024 ESMO Congress.
September 16, 2024 | 7:39 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sutro Biopharma's stock is trading lower after presenting updated data from their Phase 1b study at the 2024 ESMO Congress. The study involves luveltamab tazevibulin in combination with bevacizumab for ovarian cancer treatment.
The decline in Sutro Biopharma's stock price is likely due to investor reaction to the updated data from the Phase 1b study. The market may have had higher expectations for the study results, leading to a negative short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100